Journal
CLINICAL AND EXPERIMENTAL OPTOMETRY
Volume 105, Issue 2, Pages 194-204Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08164622.2021.1984179
Keywords
Biomarker; imaging; neurodegenerative diseases; retina
Categories
Funding
- Alzheimer's Drug Discovery Foundation [RDAPB 201809]
- National Foundation for Medical Research and Innovation [Mason Foundation Portfolio 3]
- H & L Hecht Trust (Perpetual Trustees) [IPAP2021/1615]
- Yulgilbar Foundation [YARP]
Ask authors/readers for more resources
Retinal imaging is a promising method for detecting features of neurodegenerative diseases, with efforts to harmonise study designs and imaging methods being crucial for translating these findings into clinical care. Eye care providers may play important roles in the future detection of a variety of neurodegenerative diseases.
The timely detection of neurodegenerative diseases is central to improving clinical care as well as enabling the development and deployment of disease-modifying therapies. Retinal imaging is emerging as a method to detect features of a number of neurodegenerative diseases, given the anatomical and functional similarities between the retina and the brain. This review provides an overview of the current status of retinal imaging biomarkers of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, Huntington's disease and multiple sclerosis. Whilst research findings are promising, efforts to harmonise study designs and imaging methods will be important in translating these findings into clinical care. Doing so may mean that eye care providers will play important roles in the detection of a variety of neurodegenerative diseases in future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available